Merck’s 15 valent conjugated pneumonia vaccine PCV15, VAXNEUVANCE™ received FDA approval for use in pediatric patients today. VAXNEUVANCE™ may be used now to prevent disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F in individuals 6 weeks of age and older.  

Medical practices requiring contracted discounts directly through Merck or vaccineshoppe.com can participate in MPPG’s Merck vaccine savings program.